Victory Capital Management Inc. Acquires 3,901 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Victory Capital Management Inc. lifted its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 2.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 142,350 shares of the company’s stock after purchasing an additional 3,901 shares during the period. Victory Capital Management Inc. owned about 0.10% of MiMedx Group worth $841,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. bought a new stake in MiMedx Group in the 3rd quarter worth $30,000. Point72 Asset Management L.P. bought a new stake in MiMedx Group in the 2nd quarter worth $40,000. Entropy Technologies LP bought a new stake in MiMedx Group in the 3rd quarter worth $64,000. Quest Partners LLC bought a new stake in MiMedx Group in the 2nd quarter worth $81,000. Finally, Aigen Investment Management LP bought a new stake in shares of MiMedx Group during the 3rd quarter valued at about $83,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Up 2.2 %

Shares of MiMedx Group stock opened at $9.43 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market capitalization of $1.39 billion, a PE ratio of 17.15 and a beta of 1.94. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $9.64. The company has a 50-day simple moving average of $6.79 and a two-hundred day simple moving average of $6.88.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MDXG shares. Craig Hallum cut their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, MiMedx Group presently has an average rating of “Buy” and an average target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.